A new drug for the treatment of follicular lymphoma will soon be reviewed in Canada by the pan-Canadian Oncology Drug Review (pCODR):
- Obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab maintenance, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab containing regimen.
If you are not familiar already, pCODR makes recommendations to the provinces and territories to help them decide whether they will provide funding for new cancer drugs. Understanding the experiences of patients and their caregivers is a key element in the pCODR review process and pCODR allows patient groups to do this through "patient submissions".
The purpose of this survey is to help Lymphoma Canada develop a complete and thorough submission to pCODR and provincial governments in Canada. Patient and caregiver input is essential, as pCODR needs to consider the opinions and experiences of those who will be most directly affected by all drug funding recommendations they make.
As a patient with follicular lymphoma, who has direct experience with obinutuzumab (Gazyva) in combination with chemotherapy and/or obinutuzumab maintenance therapy, we invite you to complete this survey to help pCODR better understand what it is like to live with follicular lymphoma and your experience with obinutuzumab (Gazyva). Your participation in this survey is important as it may help improve access to this drug for patients in Canada. The greater the response to this survey, the better
our submission will be to pCODR.
You do not have to be a Canadian resident to respond to this survey; we appreciate input from every follicular lymphoma patient.
We at Lymphoma Canada thank you in advance for your contribution and greatly appreciate your participation in this survey. If you have any questions, concerns, or technical difficulties while completing this survey please contact Elizabeth Lye at: elizabeth@lymphoma.ca.
The deadline to complete this survey is Friday, October 28, 2016 at midnight Pacific Time.
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used without reference to a patient name or any other information that could identify the patient.
